Associate Professor, Medicine, Duke University School of Medicine
Cardiology
Dr. Kenneth Mahaffey, MD
|
|
Give Review
Dr. Kenneth Mahaffey works in the field of Cardiology. He attended University of Washington School of Medicine. He over the years received 1 awards: "Fellow (FACC)". Kenneth Mahaffey is also a published physician. He has 63 publication published. The most recent publication is: Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. Kenneth Mahaffey is registered with Medicare.
Publications
- The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
- Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.
- Cytokines profile in Hypertensive patients with left ventricular remodeling and dysfunction.
- Heart rate is associated with progression of atrial fibrillation, independent of rhythm.
- Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Stan...
- Digoxin use in patients with Atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhi...
- The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
- Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Co...
- Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and Aortic valve dis...
- Use and Outcomes Associated with Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation: Findings from the Outcomes Registry for Better Inf...
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following Acute coronary syndromes: Rationale and design of the ODYSSEY Outc...
- Higher risk of death and stroke in patients with persistent vs. paroxysmal Atrial fibrillation: results from the ROCKET-AF Trial.
- Challenges and Priorities for Research: A Report From the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thromb...
- Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Tri...
- Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular Atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Fac...
- No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial:...
- Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Bette...
- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation Acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
- Use and outcomes of antiarrhythmic therapy in patients with Atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial.
- Physician practices regarding contraindications to oral anticoagulation in Atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of At...
- Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
- Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antag...
- Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial).
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF.
- Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury.
- Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis.
- Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with Acute coronary syndrome: Com...
- Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery Disease and non-valvular atrial fibrillation: insights from ROCKET AF.
- Effect of cangrelor on periprocedural outcomes in percutaneous Coronary interventions: a pooled analysis of patient-level data.
- Five-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial.
- Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial.
- Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial.
- Ischaemic cardiac outcomes in patients with Atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
- The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*.
- Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better ...
- Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?
- Use of evidence-based cardiac prevention therapy among outpatients with Atrial fibrillation.
- Stent Thrombosis with Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes: An Analysis from the Prospective Randomized PLATO Trial.
- Prognostic significance of bleeding location and severity among patients with Acute coronary syndromes.
- Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes.
- Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation Acute coron...
- Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial.
- Cardiac Troponin after Percutaneous Coronary Intervention and 1-Year Mortality in NSTE ACS Using Systematic Evaluation of Biomarker Trends.
- Rate versus rhythm control for management of Atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibri...
- Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes: Incidence, Angiographic Characteristics, and Clinical Outcomes.
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events.
- Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
- Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in Acute coronary syndrome (TRA{middle dot}CER) trial.
- Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with Acute coronary syndromes: insigh...
- Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy.
- Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Dail...
- A novel approach to systematically implement the universal definition of Myocardial infarction: insights from the CHAMPION PLATFORM trial.
- Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (R...
- Antithrombotic therapy for atrial fibrillation and Coronary artery disease in older patients.
- Influence of body mass index on the efficacy of revascularization in patients with Coronary artery disease.
- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous Coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
- Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
- Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment.
- Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials.
- Native Valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
- Use of thienopyridine prior to presentation with non-ST-segment elevation Acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from ...
- Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry.
Schools
University of Washington
University Ariz Health Science Center
Duke University Med Center
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
Duke University Hospital -
University of Arizona -
University of Washington School of Medicine
Hospital
-
Stanford Health Care -
Duke University Hospital
Drug Facts
| NPI NUMBER | 1659455707 | |
| NPPES Provider LastName | MAHAFFEY | |
| NPPES Provider FirstName | KENNETH | |
| NPPES Provider ZIPCode | 943052200 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 135.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659455707 |
| Last Name Of The Provider | MAHAFFEY |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Andrew P. Ambrosy, MD |
|
|
Dr. Stephen A. Gaeta, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aslan T. Turer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brett J. Goodwin, MD |